Histone deacetylase inhibition leads to regulatory histone mark alterations and impairs meiosis in oocytes

Histone deacetylase inhibition leads to regulatory histone mark alterations and impairs meiosis in oocytes

Abstract Background Panobinostat (PB), a histone deacetylase (HDAC) inhibitor drug, is clinically used in the treatment of cancers. We investigated the effects of PB on murine ovarian functions in embryos and adult animals. Methods C57BL/6J mice were treated with 5 mg/kg PB on alternate days from em...

Full description

Bibliographic Details
Main Authors: Louis Legoff, Ouzna Dali, Elena De La Mata Santaella, Christian Jaulin, Shereen Cynthia D’Cruz, Fatima Smagulova
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Epigenetics & Chromatin
Subjects:
Panobinostat
HDAC
Epigenetics
RNA-seq
Ovary
Histone modifications
Online Access:https://doi.org/10.1186/s13072-021-00413-8

Internet

https://doi.org/10.1186/s13072-021-00413-8

Similar Items